Transforming growth factor-β neutralizing antibodies inhibit subretinal fibrosis in a mouse model

International Journal of Ophthalmology

Volumn 5, Issue 3, 2012, Pages 307-311

  Zhang, Han ^a   Liu, Zhe Li ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Subretinal fibrosis; Transforming growth factor ; Transforming growth factor neutralizing antibody

Indexed keywords

EID: 84879195182     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2012.03.11     Document Type: Article

References (31)

1. Fine SL, Berger JW, Maguire M.G., Ho A C. Age-related macular degeneration. N Engl J Med. 2000;342(7):483-492.
2. Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007;117(3):576-586.
3. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis. 2003;9:747-755.
4. Rosenfeld PJ, Shapiro H, Tuomi L., Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118(3):523-530.
5. Martin DF, Maguire MG, Ying G.S., Grunwald JE, Fine SL, Jaffe GJ Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
6. Rosenfeld PJ, Brown DM, Heier J.S., Boyer DS, Kaiser PK, Chung CY, Kim RY Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
7. Brown DM, Kaiser PK, Michels M, Soubrane G., Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
8. Takeda A, Baffi JZ, Kleinman M.E., Cho WG, Nozaki M, Yamada K, Kaneko H., Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J. CCR 3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460(7252):225-230.
9. Hwang JC, Del Priore LV, Freund KB, Chang S, Iranmanesh R. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42(1):6-11.
10. Jo Y.J., Sonoda KH, Oshima Y, Takeda A., Kohno R, Yamada J, Hamuro J., Yang Y, Notomi S, Hisatomi T, Ishibashi T. Establishment of a new animal model of focal subretinal fibrosis that resembles disciform lesion in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(9):6089-6095.
11. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791.
12. Brown PD, Wakefield LM, Levinson A D, Sporn MB Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors. 1990;3(1):35-43.
13. Lyons RM, Gentry LE, Purchio A.F., Moses HL Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990;110(4):1361-1367.
14. Miyazono K, Heldin CH Role for carbohydrate structures in TGF-beta 1 latency. Nature 1989. 1989;338(6211):158-160.
15. Border WA, Noble NA Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331(19):1286-1292.
16. Connor TB, Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83(5):1661-1666.
17. Kita T, Hata Y, Kano K., Miura M, Nakao S, Noda Y., Shimokawa H, Ishibashi T. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes. 2007;56(1):231-238.
18. Bochaton-Piallat M.L., Kapetanios AD, Donati G, Redard M., Gabbiani G, Pournaras CJ TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci. 2000;41(8):2336-2342.
19. Amin R, Puklin JE, Frank RN Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35(8):3178-3188.
20. Ogata N, Yamamoto C, Miyashiro M, Yamada H., Matsushima M, Uyama M. Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization. Curr Eye Res. 1997;16(1):9-18.
21. Yamamoto T, Katayama I, Nishioka K. Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol. 1999;26(3):609-615.
22. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210.
23. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-1358.
24. Forrester JV, Lumsden L, Liversidge J., Kuppener M, Mesri M. Immunoregulation of uveoretinal inflammation. Prog Retin Eye Res. 1995;14(2):393-412.
25. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992;36(5):373-384.
26. Recalde S, Zarranz-Ventura J, Fernandez-Robredo P, Garcia-Gomez PJ, Salinas-Alaman A, Borras-Cuesta F, Dotor J, Garcia-Layana A. Transforming growth factor-beta inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. Invest Ophthalmol Vis Sci. 2011;52(10):7090-7097.
27. Pasquale LR, Dorman-Pease ME, Lutty G.A., Quigley HA, Jampel HD Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34(1):23-30.
28. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5(4):200-206.
29. Leask A, Abraham DJ TGF-beta signaling and the fibrotic response. FASEB J. 2004;18(7):816-827.
30. Nagineni CN, Samuel W, Nagineni S., Pardhasaradhi K, Wiggert B, Detrick B., Hooks JJ. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197(3):453-462.
31. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007;84(5):812-822.